Equities Analysts Offer Predictions for BEAM Q3 Earnings

Key Points

• Leerink Partners has raised its Q3 2025 earnings estimate for Beam Therapeutics to ($1.05) per share, a slight improvement from the previous estimate of ($1.06).
• Beam Therapeutics reported a loss of ($1.00) per share for the recent quarter, surpassing analyst expectations, but revenues fell to $8.47 million, significantly lower than the forecast of $13.29 million.
• Barclays and Wells Fargo have both lowered their price targets for Beam Therapeutics, reflecting mixed analyst ratings with a consensus rating of "Buy" and a target price of $48.45.

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Leerink Partnrs increased their Q3 2025 earnings estimates for shares of Beam Therapeutics in a research report issued on Tuesday, August 5th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1.05) per share for the quarter, up from their prior forecast of ($1.06). The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. Leerink Partnrs also issued estimates for Beam Therapeutics' Q4 2025 earnings at ($1.17) EPS, FY2025 earnings at ($4.44) EPS and FY2026 earnings at ($4.40) EPS.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($1.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.04) by $0.04. Beam Therapeutics had a negative net margin of 661.31% and a negative return on equity of 43.15%. The business had revenue of $8.47 million during the quarter, compared to analysts' expectations of $13.29 million. During the same period in the prior year, the company earned ($1.11) EPS. The firm's quarterly revenue was down 28.0% compared to the same quarter last year.

Several other brokerages have also recently issued reports on BEAM. Cantor Fitzgerald upgraded shares of Beam Therapeutics to a "strong-buy" rating in a research report on Monday, July 21st. Wells Fargo & Company decreased their price target on shares of Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Guggenheim decreased their price target on shares of Beam Therapeutics from $78.00 to $55.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Barclays decreased their price target on shares of Beam Therapeutics from $25.00 to $21.00 and set an "equal weight" rating for the company in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $48.45.

Beam Therapeutics Stock Down 1.4%

NASDAQ BEAM traded down $0.24 on Friday, hitting $16.93. The company's stock had a trading volume of 1,836,804 shares, compared to its average volume of 2,052,646. Beam Therapeutics has a 1-year low of $13.52 and a 1-year high of $35.25. The company's 50-day moving average is $18.86 and its 200 day moving average is $20.88. The firm has a market cap of $1.71 billion, a PE ratio of -3.76 and a beta of 2.22.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Northern Trust Corp boosted its stake in Beam Therapeutics by 7.2% during the fourth quarter. Northern Trust Corp now owns 740,506 shares of the company's stock worth $18,365,000 after acquiring an additional 49,415 shares in the last quarter. GAMMA Investing LLC boosted its stake in Beam Therapeutics by 549.9% during the first quarter. GAMMA Investing LLC now owns 37,185 shares of the company's stock worth $726,000 after acquiring an additional 31,463 shares in the last quarter. Amalgamated Bank boosted its stake in Beam Therapeutics by 20.4% during the first quarter. Amalgamated Bank now owns 3,153 shares of the company's stock worth $62,000 after acquiring an additional 534 shares in the last quarter. Stifel Financial Corp boosted its stake in Beam Therapeutics by 27.8% during the fourth quarter. Stifel Financial Corp now owns 13,662 shares of the company's stock worth $339,000 after acquiring an additional 2,976 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in Beam Therapeutics by 11.9% during the first quarter. Rhumbline Advisers now owns 141,204 shares of the company's stock worth $2,758,000 after acquiring an additional 14,971 shares in the last quarter. 99.68% of the stock is owned by institutional investors.

Insider Activity at Beam Therapeutics

In related news, insider Fmr Llc sold 48,374 shares of the stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $20.50, for a total transaction of $991,667.00. Following the transaction, the insider directly owned 2,073,665 shares of the company's stock, valued at $42,510,132.50. This represents a 2.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 49,624 shares of company stock valued at $1,015,628. Corporate insiders own 3.50% of the company's stock.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.